Skip to content

EPS (Basic) at other companies

Pfizer logo
PfizerPFE
$0.47-9.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.17-52.5%
Merck & Co. logo
Merck & Co.MRK
-$1.72-186%
Incyte logo
IncyteINCY
$1.52+85.4%
Gilead Sciences logo
Gilead SciencesGILD
$1.63+53.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.97+2,363%

Other financials

Income statement

See full
Revenue$11.5B+2.6%
Gross profit$8.1B-1.2%
Net income$2.7B+9.0%
EPS (diluted)$1.31+9.2%

Balance sheet

See full
Cash & equivalents$9.6B-12.0%
Total debt$44.7B-10.5%
Total equity$20.1B+15.4%
Total assets$86.5B-6.4%

Cash flow

See full
Operating cash flow$1.1B-43.5%
CapEx$347.0M+33.5%
Free cash flow$757.0M-55.3%

Valuation

See full
Market cap$117.66B+23.9%
Enterprise value$152.75B+16.0%
P/E16.2×-2.9×
P/S2.4×+0.4×

Profitability

See full
Gross margin70.5%0.0pp
Net margin15%+3.8pp
FCF margin24.6%-2.9pp

Returns & leverage

See full
Return on equity38.8%+7.3pp
Debt / equity2.2×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bristol-Myers Squibb's EPS (basic)?
Bristol-Myers Squibb (BMY) reported EPS (basic) of $1.31 in Q1 2026.
How has Bristol-Myers Squibb's EPS (basic) changed year-over-year?
Bristol-Myers Squibb's EPS (basic) increased by 8.3% year-over-year, from $1.21 to $1.31.
What is the long-term trend for Bristol-Myers Squibb's EPS (basic)?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's EPS (basic) has grown at a 2.5% compound annual growth rate (CAGR), from $3.14 to $3.47.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.